<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01741090</url>
  </required_header>
  <id_info>
    <org_study_id>CR109021</org_study_id>
    <nct_id>NCT01741090</nct_id>
  </id_info>
  <brief_title>The Effectiveness and Safety for Mesenchymal Stem Cell for Alcoholic Liver Cirrhosis</brief_title>
  <official_title>The Evaluation of Effectiveness and Safety for New Therapy With Bone Marrow Derived Autologous Mesenchymal Stem Cell for Hepatic Failure Caused by Alcoholic Liver Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background &amp; Aim: Bone marrow derived mesenchymal stem cells (BM-MSCs) have capacity to
      differentiate into hepatocytes and anti-fibrotic effect in the experimental model. No study
      was done in humans with alcoholic liver cirrhosis. The researchers investigated the
      anti-fibrotic effect of BM-MSCs in alcoholic cirrhosis as Phase II clinical study.

      Methods: Eleven alcoholic cirrhosis patients (M:F = 10:1) with Child-Pugh's class B and
      maintenance of alcohol abstinence at least 2 months were enrolled. At baseline, all patients
      received liver biopsy, hepatic venous pressure gradient (HVPG) measurement and serologic
      tests. BM-MSCs were isolated from each patient's BM and amplified for one month and injected
      two times at 4, 8week through Rt. hepatic artery. 5x106cells/mL of BM-MSCs were injected in
      each session. Follow up biopsy, HVPG and relative expression of tissue transforming growth
      factor-1 (TGF-β1), α smooth muscle actin (α-SMA) and collagen-1 by real time RT PCR were
      measured after 12weeks from 2nd BM-MSC injection. The primary outcome was improvement in
      patients' histology Aim :

      The researchers aimed to evaluate safety and effectiveness of new therapy with bone marrow
      derived autologous mesenchymal stem cell for hepatic failure caused by alcoholic liver
      cirrhosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autologous BM-MSCs therapy in alcoholic cirrhosis induces improvement of hepatic fibrosis in
      histological and quantitative measurements.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The improvement of Liver Histologic grade</measure>
    <time_frame>6 months later</time_frame>
    <description>according to Metavir and Laennec fibrosis scoring system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The evaluation of hepatic dendritic cells activity by immunohistochemistry</measure>
    <time_frame>baseline and 6 months later</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver fibrosis quantitative analysis using Hydroxyproline contents in liver tissue</measure>
    <time_frame>baseline and 6 months later</time_frame>
    <description>Hydroxyproline is a essential component of collange fiber</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Real-Time Polymerase Chain Reaction for relative mRNA expression of TGF-beta, collagen, procollagen, MMP2 or 9</measure>
    <time_frame>baseline and 6 months later</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic venous pressure gradient(HVPG)</measure>
    <time_frame>baseline and 6 months later</time_frame>
    <description>HVPG is a gold standard to measure the portal hypertension.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic vein arrival time using microbubble contrast enhanced ultrasonography</measure>
    <time_frame>baseline and 6 months later</time_frame>
    <description>Hepatic vein arrival time is related with portal hypertension and intrahepatic inflammation, neoangiogenesis and shunts formation secondary to hepatic fibrosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver stiffness measurement with transient elastography</measure>
    <time_frame>baseline and 6 months later</time_frame>
    <description>Recently, hepatic fibrosis can be estimated non-invasively using transient elastography (Fibroscan, commercial name) and it can be additive data in estimation of therapeutic response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child-Pugh score</measure>
    <time_frame>baseline and 6 months later</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MELD score</measure>
    <time_frame>baseline and 6 months later</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Alcoholic Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>MSC injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This study is designed as single interventional arm without comparative arm. MSC injection means hepatic artery catheterizations and mesenchymal stem cell injection through catheter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mesenchymal stem cell injection</intervention_name>
    <description>Hepatic artery catheterization and mesenchymal stem cell injection will be used in alcoholic liver cirrhosis. And before and 1 month after injection, change of liver cirrhosis and portal hypertension will be evaluated.</description>
    <arm_group_label>MSC injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Alcoholic liver cirrhosis(child Pugh class B or C, ≥ 7 scores),confirmed by clinically
             or biopsy.

          2. Stop drinking over past 6months.

          3. Patients agree with informed consent Patients must satisfy all inclusion criteria.

        Exclusion Criteria:

          1. Patients who did not satisfy inclusion criteria

          2. Hepatocellular carcinoma

          3. Pregnancy or breast feeding

          4. Infective disease(HIV, HBV, HCV..)

          5. Other incurable malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soon Koo Baik, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University Wonju College of Medicine Department of Internal Medicine Devision of Gastroenterology and Hepatology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Soon Koo Baik, M.D., PhD</last_name>
    <phone>82-33-741-1229</phone>
    <email>baiksk@medimail.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Moon Young Kim, M.D., PhD</last_name>
    <phone>82-33-741-1225</phone>
    <email>drkimmy@yonsei.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yonsei University Wonju College of Medicine Wonju Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <state>Kangwon-do</state>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soon Koo Baik, M.D</last_name>
      <phone>82-33-741-1229</phone>
      <email>baiksk@medimail.co.kr</email>
    </contact>
    <contact_backup>
      <last_name>Moon Young Kim, M.D</last_name>
      <phone>82-33-741-1225</phone>
      <email>drkimmy@yonsei.ac.kr</email>
    </contact_backup>
    <investigator>
      <last_name>Soon Koo Baik, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Moon Young Kim, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Kountouras J, Billing BH, Scheuer PJ. Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br J Exp Pathol. 1984 Jun;65(3):305-11.</citation>
    <PMID>6743531</PMID>
  </reference>
  <reference>
    <citation>Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol. 1995 Dec;19(12):1409-17.</citation>
    <PMID>7503362</PMID>
  </reference>
  <reference>
    <citation>Hong SH, Gang EJ, Jeong JA, Ahn C, Hwang SH, Yang IH, Park HK, Han H, Kim H. In vitro differentiation of human umbilical cord blood-derived mesenchymal stem cells into hepatocyte-like cells. Biochem Biophys Res Commun. 2005 May 20;330(4):1153-61.</citation>
    <PMID>15823564</PMID>
  </reference>
  <reference>
    <citation>Lee KD, Kuo TK, Whang-Peng J, Chung YF, Lin CT, Chou SH, Chen JR, Chen YP, Lee OK. In vitro hepatic differentiation of human mesenchymal stem cells. Hepatology. 2004 Dec;40(6):1275-84.</citation>
    <PMID>15562440</PMID>
  </reference>
  <reference>
    <citation>Kang XQ, Zang WJ, Bao LJ, Li DL, Song TS, Xu XL, Yu XJ. Fibroblast growth factor-4 and hepatocyte growth factor induce differentiation of human umbilical cord blood-derived mesenchymal stem cells into hepatocytes. World J Gastroenterol. 2005 Dec 21;11(47):7461-5.</citation>
    <PMID>16437717</PMID>
  </reference>
  <reference>
    <citation>Kallis YN, Alison MR, Forbes SJ. Bone marrow stem cells and liver disease. Gut. 2007 May;56(5):716-24. Epub 2006 Dec 4. Review.</citation>
    <PMID>17145739</PMID>
  </reference>
  <reference>
    <citation>Wang JA, Luo RH, Zhang X, Xie XJ, Hu XY, He AN, Chen J, Li JH. Bone marrow mesenchymal stem cell transplantation combined with perindopril treatment attenuates infarction remodelling in a rat model of acute myocardial infarction. J Zhejiang Univ Sci B. 2006 Aug;7(8):641-7.</citation>
    <PMID>16845718</PMID>
  </reference>
  <reference>
    <citation>Kim MY, Cho MY, Baik SK, Park HJ, Jeon HK, Im CK, Won CS, Kim JW, Kim HS, Kwon SO, Eom MS, Cha SH, Kim YJ, Chang SJ, Lee SS. Histological subclassification of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension. J Hepatol. 2011 Nov;55(5):1004-9. doi: 10.1016/j.jhep.2011.02.012. Epub 2011 Feb 24.</citation>
    <PMID>21354227</PMID>
  </reference>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2011</study_first_submitted>
  <study_first_submitted_qc>December 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2012</study_first_posted>
  <last_update_submitted>December 7, 2012</last_update_submitted>
  <last_update_submitted_qc>December 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yonsei University</investigator_affiliation>
    <investigator_full_name>Moon Young Kim</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Autologous Mesenchymal stem cell</keyword>
  <keyword>alcoholic liver cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Cirrhosis, Alcoholic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

